MétaCan
Menu
Back to cohort
Record W2086202199 · doi:10.4088/jcp.12m07767

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Safety, and Tolerability of Extended-Release Metadoxine in Adults With Attention-Deficit/Hyperactivity Disorder

2012· article· en· W2086202199 on OpenAlexfundno aff
Iris Manor, Rachel Ben‐Hayun, Judith Aharon‐Peretz, Dana Salomy, Abraham Weizman, Yaron Daniely, Dalia Megiddo, Jeffrey H. Newcorn, Joseph Biederman, Lenard A. Adler

Bibliographic record

VenueThe Journal of Clinical Psychiatry · 2012
Typearticle
Languageen
FieldMedicine
TopicAttention Deficit Hyperactivity Disorder
Canadian institutionsnot available
FundersCilagH. Lundbeck A/SUniversity of CambridgeBristol-Myers SquibbEli Lilly and CompanyAstraZenecaYork UniversityMassachusetts General HospitalTeva Pharmaceutical IndustriesTel Aviv UniversitySanofiPfizerMajor League Baseball
KeywordsTolerabilityPlaceboNauseaAttention deficit hyperactivity disorderMedicineAdverse effectRating scaleInternal medicinePsychologyPsychiatryDevelopmental psychology

Abstract

OBJECTIVE: To evaluate the efficacy, safety, and tolerability of an oral extended-release (ER) formulation of the nonstimulant metadoxine in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). METHOD: This was a 1:1 randomized, double-blind, placebo-controlled, parallel-design, phase 2 study of metadoxine ER 1,400 mg/d treatment for 6 weeks, following a 2-week baseline/screening period, involving 120 adults with DSM-IV-defined ADHD. A follow-up assessment occurred 2 weeks after the trial was completed. Efficacy measures included changes in Conners' Adult ADHD Rating Scale-Investigator Rated (CAARS-INV) total ADHD symptoms score with adult ADHD prompts (primary measure), response rates (≥ 25% or 40% improvement in CAARS-INV total ADHD symptom score), Test of Variables of Attention (TOVA) performance, and Adult ADHD Quality of Life (AAQoL) total score. The study was conducted from March 15, 2011, to August 21, 2011. RESULTS: Intent-to-treat analysis revealed that subjects receiving metadoxine ER showed statistically significant improvement in CAARS-INV total ADHD symptoms score (P = .02), higher rate of response (≥ 25% [P = .03] or ≥ 40% [P = .04] improvement) on the CAARS-INV total ADHD symptoms score, and improvement in TOVA score (P = .02) and AAQoL score (P = .01) compared with the placebo group. Improvements in ADHD symptoms (scored by CAARS-INV) were significantly different in subjects treated with metadoxine ER versus placebo as early as 2 weeks following treatment initiation. Metadoxine ER was generally well tolerated, with nausea (17% [10/58] vs 0% [0/59]), fatigue (31% [18/58] vs 27% [16/59]), and headaches (29% [17/58] vs 39% [23/59]) being the most frequently reported adverse effects for the metadoxine ER and placebo groups, respectively. CONCLUSIONS: Findings suggest that metadoxine ER is a well-tolerated and effective treatment for adults with ADHD. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01243242.

Stored with the screening record, where it is evidence for the labels above.

How this classification was reachedexpand

The three-model screen

all 5,600 screened works →

All three models called this out of scope.

stratum: fund_new · design weight: 1678.90 (the sample is stratified; any rate computed without the weight is wrong)
Claude Opus 4.8OUT
genre: empirical
about Canada: no
confidence: high

Randomized placebo-controlled drug trial in adult ADHD; a trial, not a study of trials.

GPT-5.6 (high)OUT
genre: empirical
about Canada: no
confidence: high

This randomized trial evaluates an ADHD treatment and does not study clinical research methods.

Grok 4.5OUT
genre: empirical
about Canada: no
confidence: high

Clinical RCT of metadoxine for adult ADHD, not a study of research methods.

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.000

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.002
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.001
Bibliometrics0.0000.000
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.070
GPT teacher head0.429
Teacher spread0.358 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations25
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueThe Journal of Clinical PsychiatrySame topicAttention Deficit Hyperactivity DisorderFrench-language works237,207